OBUS NELSON 4

What Happened

• Obus Nelson, a director of Lifecore Biomedical, Inc. (LFCR), was granted 25,907 restricted stock units (RSUs) on June 4, 2026. The award is reported as an acquisition (grant); no cash price is shown (N/A).
• Each RSU converts into one share of common stock on a 1:1 basis (Footnote F1). Because this is a compensation award (not an open-market purchase or sale), it is generally a non‑market transaction.

Key Details

• Transaction date: June 4, 2026. Form 4 filed June 5, 2026 (timely filing).
• Shares/units granted: 25,907 RSUs. No purchase price (N/A) and no immediate monetary value disclosed in the filing.
• Shares owned after transaction: Not specified in the provided excerpt.
• Footnotes: F1 — RSUs convert 1-for-1 to common stock. F2 — Vesting occurs on the earlier of June 4, 2027 or the company’s 2027 annual meeting, provided that meeting is at least 50 weeks after June 4, 2026.
• Transaction code: A (award/grant).

Context

• RSU grants are a common form of director compensation and vest over time; they do not necessarily indicate immediate buying or selling sentiment. The economic value of this award will depend on LFCR’s share price when the RSUs convert/vest.
• No sale or exercise occurred in this filing; the units are subject to future vesting conditions described above.